



October 31, 2025

Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito; hereinafter, the “Company”) announced that the disposal of treasury shares (hereinafter, the “disposal”) related to the Post-delivery Type Performance-linked stock remuneration plan was completed today based on the Board of Directors resolution of October 1, 2025, details of which are provided below. Please see Santen’s release on “Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan” dated October 1, 2025 for more details.

Details

Outline of the disposal

(1) Type and number of shares to be disposed of	57,909 shares of the Company's common stock
(2) Disposal price	1,639.5 yen per share
(3) Total amount of share disposal	94,941,804 yen
(4) Recipients of allotment of shares to be disposed of, number thereof, and number of shares allotted to be disposed of	2 Directors (outside directors excluded): 11,918 shares 4 Corporate officers: 18,529 shares 2 leavers: 27,462 shares
(5) Disposal date	October 31, 2025

Contact:

Guillaume Sakuma

Global Head of Investor Relations

E-mail: ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “*Tenki ni sanyo suru*,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission

is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience "Happiness with Vision."

For more information, please visit Santen's website <https://www.santen.com/en>.